Characterization and Functional Significance of the von Hippel-Lindau Gene in Renal Cell Carcinomas

  • H.-J. H. Decker
  • S. Klauck
  • D. I. Smith
  • C. Huber
  • B. Seizinger
Conference paper


The von Hippel-Lindau (VHL) syndrome is an autosomal dominant inherited pleiotropic disorder with virtually complete penetrance and highly variable expressivity. Carriers of the gene have increased susceptibility to a variety of neoplasms of mesodermal and neuroectodermal origin. The most characteristic and frequently observed lesions in VHL are angiomatosis retinae (52%–58%), cerebellar and spinal hemangioblastoma (38%–66%), pheochromocytoma (17%–26%), pancreatic and renal cysts (8%–72% and 25%–60%, respectively; [8] and others). Of those affected by the syndrome, 17%–55% suffer from renal cell carcinoma (RCC), which is one of the most serious and life-threatening complications of the disease. Compared to counterparts with the sporadic form, RCCs in VHL patients occur at an earlier age and are often bilateral or multifocal and are associated with renal cysts. In contrast to simple cysts in the general population, which are usually benign, renal cysts in VHL may contain occult carcinomas. After onset the malignant potential of RCC in VHL is similar to that in the sporadic type, often complicated by metastasis and de novo recurrences. While many VHL patients survive surgery of hemangioblastoma, up to one-third of these patients die of RCC. The incidence of VHL is approximately 1:100000, but it is possible that there are geographic variations, with a regional incidence of 1:40 000. There is as yet no sufficient explanation for the primary biochemical defect in VHL or for the variable constellation of tissue type involved in tumor formation. Recent advances in tumor cytogenetics and molecular genetics provide the tools necessary to search for genetic defects in VHL. With the advent of reverse genetics it has become possible to isolate and characterize genes of interest without any hint of their possible functions.


Renal Cell Carcinoma Renal Cyst Cosmid Probe Probe 233E2 Bilateral Renal Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bergerheim US, Frisk B, Stellan B, Collins VP, Zech L (1990) del(3p) (pl3p21) in renal cell adenoma and del(4p) (pi4) in bilateral renal cell carcinoma in two unrelated patients with von Hippel-Lindau disease. Cancer Genet Cytogenet 49: 125–131PubMedCrossRefGoogle Scholar
  2. 2.
    Decker HJ, Neumann HP, Walter TA, Sandberg A A (1988) 3p involvement in a renal cell carcinoma in von Hippel-Lindau syndrome. Region of tumor breakpoint clustering on 3p. Cancer Genet Cytogenet 33: 59–65PubMedCrossRefGoogle Scholar
  3. 3.
    Decker HJ, Gemmill RM, Neumann HP, Walter TA, Sandberg AA (1989) Loss of heterozygosity on 3p in a renal cell carcinoma in von Hippel-Lindau syndrome. Cancer Genet Cytogenet 39: 289–293PubMedCrossRefGoogle Scholar
  4. 4.
    Decker HJ, Klauck SM, Lawrence JB, McNeil J, Smith D, Gemmill RM, Sandberg A A, Neumann HP, Simon B, Green J, Seizinger BR (1993) Cytogenetic and fluorescence in-situ hybridization studies on sporadic and hereditary tumors associated with von Hippel-Lindau syndrome (VHL). Cancer Genet Cytogenet (to be published)Google Scholar
  5. 5.
    Goodman MD, Goodman BK, Lubin MB, Braunstein G, Rotter JL, Schreck RR (1990) Cytogenetic characterization of renal cell carcinoma in von Hippel-Lindau syndrome. Cancer 65: 1150–1154PubMedCrossRefGoogle Scholar
  6. 6.
    Hosoe S, Brauch H, Latif F, Glenn G, Daniel L, Bale S, Choyke P, Gorin M, Oldfield E, Berman A et al. (1990) Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3. Genomics 8: 634–640PubMedCrossRefGoogle Scholar
  7. 7.
    Jordan DK, Patil SR, Divelbiss JE, Vemuganti S, Headley C, Waziri MH, Gurll NJ (1990) Cytogenetic abnormalities in tumors of patients with von Hippel-Lindau disease. Cancer Genet Cytogenet 42: 227–241CrossRefGoogle Scholar
  8. 8.
    King CR, Schimke RN, Arthur T, Davoren B, Collins D (1987) Proximal 3p deletion in renal cell carcinoma cells from a patient with von Hippel-Lindau disease. Cancer Genet Cytogenet 27: 345–348PubMedCrossRefGoogle Scholar
  9. 9.
    Kiechle-Schwarz MH, Neumann PH, Decker HJH, Dietrich C, Wullich B, Schempp W (1989) Cytogenetic studies on three pheochromocytomas derived from patients with von Hippel-Lindau syndrome. Hum Genet 82: 127–130PubMedCrossRefGoogle Scholar
  10. 10.
    Kovacs G, Hsiang-Fu K (1991) Nonhomologous chromatid exchange in hereditary and sporadic renal cell carinomas. Pro Natl Acad Sci USA 88: 194–198CrossRefGoogle Scholar
  11. 11.
    Latif F, Tory K, Gnarra J, Masahiro Y, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, Walther MM, Weng Y, Duan DSR, Dean M, Glavac D, Richards FM, Crossey PA, Ferguson-Smith MA, Paslier DL, Chumakov I, Cohen D, Chinault C, Mäher E, Linehan WM, Zbar B, Lerman MI (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317–1320PubMedCrossRefGoogle Scholar
  12. 12.
    Mäher ER, Yates JR, Ferguson Smith MA (1990) Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma. J Med Genet 27: 311–314PubMedCrossRefGoogle Scholar
  13. 13.
    Neumann HP (1987) Basic criteria for clinical diagnosis and genetic counselling in von Hippel-Lindau syndrome. Vasa 16: 220–226PubMedGoogle Scholar
  14. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, Haines JM, Yuen JW, Collins D, Majoor Krakauer D et al. (1988) Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332: 268–269PubMedCrossRefGoogle Scholar
  15. 15.
    Seizinger BR, Smith DI, Filling-Katz MR, Neumann HP, Green JS, Choyke PL, Anderson KM, Freiman RN, Klauck SM, Whaley JM, Decker HJ et al. (1991) Genetic flanking markers refine diagnostic criteria and provide new insights into the genetics of von Hippel Lindau disease. Proc Natl Acad Sci USA 88: 2864–2868PubMedCrossRefGoogle Scholar
  16. 16.
    Tory K, Brauch H, Linehan M, Barba D, Oldfield E, Filling Katz M, Seizinger B, Nakamura Y, White R, Marshall FF et al. (1989) Specific genetic change in tumors associated with von Hippel-Lindau disease. J Natl Cancer Inst 81: 1097–1101PubMedCrossRefGoogle Scholar
  17. 17.
    Vance JM, Small KW, Jones MA, Stajich JM, Yamaoka LH, Roses AD, Hung WY, Pericak Vance MA (1990) Confirmation of linkage in von Hippel-Lindau disease. Genomics 6: 565–567PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • H.-J. H. Decker
    • 1
    • 2
  • S. Klauck
    • 1
  • D. I. Smith
    • 3
  • C. Huber
    • 2
  • B. Seizinger
    • 1
  1. 1.Molecular Neuro-Oncology Laboratory, Harvard Medical SchoolMassachusetts General HospitalBostonUSA
  2. 2.Abteilung Hämatologie IIIMedizinische Klinik des UniversitätMainzGermany
  3. 3.Department of Molecular Biology and GeneticsWayne State UniversityDetroitUSA

Personalised recommendations